71 related articles for article (PubMed ID: 25688104)
1. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
Gonzalez-Angulo AM; Krop I; Akcakanat A; Chen H; Liu S; Li Y; Culotta KS; Tarco E; Piha-Paul S; Moulder-Thompson S; Velez-Bravo V; Sahin AA; Doyle LA; Do KA; Winer EP; Mills GB; Kurzrock R; Meric-Bernstam F
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25688104
[TBL] [Abstract][Full Text] [Related]
2. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Smyth LM; Monson KR; Jhaveri K; Drilon A; Li BT; Abida W; Iyer G; Gerecitano JF; Gounder M; Harding JJ; Voss MH; Makker V; Ho AL; Razavi P; Iasonos A; Bialer P; Lacouture ME; Teitcher JB; Erinjeri JP; Katabi N; Fury MG; Hyman DM
Invest New Drugs; 2017 Dec; 35(6):742-750. PubMed ID: 28281183
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
Azad N; Perroy A; Gardner E; Imamura CK; Graves C; Sarosy GA; Minasian L; Kotz H; Raggio M; Figg WD; Kohn EC
Cancer Biol Ther; 2009 Oct; 8(19):1800-5. PubMed ID: 19738417
[TBL] [Abstract][Full Text] [Related]
4. Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.
Schott AF; Goldstein LJ; Cristofanilli M; Ruffini PA; McCanna S; Reuben JM; Perez RP; Kato G; Wicha M
Clin Cancer Res; 2017 Sep; 23(18):5358-5365. PubMed ID: 28539464
[No Abstract] [Full Text] [Related]
5. A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.
Kalogera E; Nevala WK; Finnes HD; Suman VJ; Schimke JM; Strand CA; Kottschade LA; Kudgus RA; Buhrow SA; Becher LR; Geng L; Glaser GE; Grudem ME; Jatoi A; Klampe CM; Kumar A; Langstraat CL; McWilliams RR; Wahner Hendrickson AE; Weroha SJ; Yan Y; Reid JM; Markovic SN; Block MS
Clin Cancer Res; 2024 Jun; 30(12):2623-2635. PubMed ID: 38530846
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors.
Gouda MA; Shunyakova J; Naing A; Dumbrava E; Hong DS; Yuan Y; Yang P; Myers A; Liang Y; Peng J; Karp D; Tsimberidou AM; Rodon J; Yap TA; Piha-Paul SA; Meric-Bernstam F; Fu S
ESMO Open; 2024 Jun; 9(6):103486. PubMed ID: 38914452
[TBL] [Abstract][Full Text] [Related]
7. Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.
Kalinsky K; Sparano JA; Zhong X; Andreopoulou E; Taback B; Wiechmann L; Feldman SM; Ananthakrishnan P; Ahmad A; Cremers S; Sireci AN; Cross JR; Marks DK; Mundi P; Connolly E; Crew KD; Maurer MA; Hibshoosh H; Lee S; Hershman DL
Clin Transl Oncol; 2018 Nov; 20(11):1474-1483. PubMed ID: 29736694
[TBL] [Abstract][Full Text] [Related]
8. Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.
Moreno V; Calvo E; Middleton MR; Barlesi F; Gaudy-Marqueste C; Italiano A; Romano E; Marabelle A; Chartash E; Dobrenkov K; Zhou H; Connors EC; Zhang Y; Wermke M
Cancer Immunol Immunother; 2022 Dec; 71(12):2985-2998. PubMed ID: 35596791
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.
Do K; Speranza G; Bishop R; Khin S; Rubinstein L; Kinders RJ; Datiles M; Eugeni M; Lam MH; Doyle LA; Doroshow JH; Kummar S
Invest New Drugs; 2015 Jun; 33(3):720-8. PubMed ID: 25637165
[TBL] [Abstract][Full Text] [Related]
10. PI3K-AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds.
Yuan Y; Long H; Zhou Z; Fu Y; Jiang B
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671478
[TBL] [Abstract][Full Text] [Related]
11. CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer.
Luque M; Cristóbal I; Sanz-Álvarez M; Santos A; Zazo S; Eroles P; Arpí O; Rovira A; Albanell J; Madoz-Gúrpide J; García-Foncillas J; Rojo F
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329936
[TBL] [Abstract][Full Text] [Related]
12. AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
Martorana F; Motta G; Pavone G; Motta L; Stella S; Vitale SR; Manzella L; Vigneri P
Front Pharmacol; 2021; 12():662232. PubMed ID: 33995085
[TBL] [Abstract][Full Text] [Related]
13. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.
Richter A; Fischer E; Holz C; Schulze J; Lange S; Sekora A; Knuebel G; Henze L; Roolf C; Murua Escobar H; Junghanss C
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803402
[TBL] [Abstract][Full Text] [Related]
14. Platelet Proteomes, Pathways, and Phenotypes as Informants of Vascular Wellness and Disease.
Aslan JE
Arterioscler Thromb Vasc Biol; 2021 Mar; 41(3):999-1011. PubMed ID: 33441027
[TBL] [Abstract][Full Text] [Related]
15. Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells
Showalter L; Czerniecki BJ; Koski GK
Oncotarget; 2020 Jul; 11(30):2873-2888. PubMed ID: 32774769
[TBL] [Abstract][Full Text] [Related]
16. Targeting AKT/PKB to improve treatment outcomes for solid tumors.
Iida M; Harari PM; Wheeler DL; Toulany M
Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136
[TBL] [Abstract][Full Text] [Related]
17. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
Chien AJ; Tripathy D; Albain KS; Symmans WF; Rugo HS; Melisko ME; Wallace AM; Schwab R; Helsten T; Forero-Torres A; Stringer-Reasor E; Ellis ED; Kaplan HG; Nanda R; Jaskowiak N; Murthy R; Godellas C; Boughey JC; Elias AD; Haley BB; Kemmer K; Isaacs C; Clark AS; Lang JE; Lu J; Korde L; Edmiston KK; Northfelt DW; Viscusi RK; Yee D; Perlmutter J; Hylton NM; Van't Veer LJ; DeMichele A; Wilson A; Peterson G; Buxton MB; Paoloni M; Clennell J; Berry S; Matthews JB; Steeg K; Singhrao R; Hirst GL; Sanil A; Yau C; Asare SM; Berry DA; Esserman LJ;
J Clin Oncol; 2020 Apr; 38(10):1059-1069. PubMed ID: 32031889
[TBL] [Abstract][Full Text] [Related]
18. Targeting AKT for cancer therapy.
Shariati M; Meric-Bernstam F
Expert Opin Investig Drugs; 2019 Nov; 28(11):977-988. PubMed ID: 31594388
[No Abstract] [Full Text] [Related]
19. Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells.
Bougen-Zhukov N; Nouri Y; Godwin T; Taylor M; Hakkaart C; Single A; Brew T; Permina E; Chen A; Black MA; Guilford P
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540244
[TBL] [Abstract][Full Text] [Related]
20. Genome atlas analysis based profiling of Akt pathway genes in the early and advanced human prostate cancer.
Alwhaibi A; Kolhe R; Gao F; Cobran EK; Somanath PR
Oncoscience; 2019 May; 6(5-6):317-336. PubMed ID: 31360736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
